Associate Director, NYU Cancer Institute
Oncology
Dr. Francisco J. Esteva, MD
|
|
Give Review
Francisco J. Esteva works in the field of Oncology. He received awards:"Elected Member" and "Fellow (FACP)". Francisco Esteva is also a published physician. He has 100 publication published. The most recent publication is: HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast Cancer.
- Comprehensive analysis of long non-coding RNAs in human breast Cancer clinical subtypes.
- Genome-Based Risk Prediction for Early Stage Breast Cancer.
- Gene Signature-Guided Dasatinib Therapy in Metastatic Breast Cancer.
- HER2-positive advanced breast Cancer: optimizing patient outcomes and opportunities for drug development.
- Effects of obesity on transcriptomic changes and Cancer hallmarks in estrogen receptor-positive breast Cancer.
- Leptomeningeal disease and breast Cancer: the importance of tumor subtype.
- Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society...
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Gu...
- Pertuzumab in the Treatment of HER2+ Breast Cancer.
- Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast Cancer.
- Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary Tumors.
- Incidence, Risk Factors, and Management of Infusion-Related Reactions in Breast Cancer Patients Receiving Trastuzumab.
- Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast Cancer.
- An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer.
- Planning Cancer control in Latin America and the Caribbean.
- Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular Carcinomas.
- Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic Breast ...
- Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast Cancer.
- Effect of HER2 status on distant recurrence in early stage breast Cancer.
- Metformin and thiazolidinediones are associated with improved breast Cancer-specific survival of diabetic women with HER2+ breast Cancer.
- Speech prosthesis aspiration.
- MEK 1/2 Inhibitor selumetinib (AZD6244) Inhibits Growth of Ovarian Clear Cell Carcinoma in a PEA-15-dependent Manner in a Mouse Xenograft Model.
- Short -term biomarker modulation prevention study of Anastrozole in Women at increased risk for second primary breast Cancer.
- Serum CD44 levels and overall survival in patients with HER2-positive breast Cancer.
- Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Bas...
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.
- Biologic and immunologic effects of preoperative trastuzumab for ductal Carcinoma in situ of the breast.
- Herceptin Conjugates Linked by EDC Boost Direct Tumor Cell Death via Programmed Tumor Cell Necrosis.
- Helicobacter pylori bacteremia with sepsis syndrome.
- Recombinant human erythropoietin antagonizes trastuzumab treatment of breast Cancer cells via Jak2-mediated Src activation and PTEN inactivation.
- PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast Cancer.
- PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast Cancer xenograft model through increased cytoplasmic localization of activated extracellular sign...
- Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast Cancer cells resistant to herceptin.
- Blood peptidome-degradome profile of breast Cancer.
- Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.
- Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast Cancer.
- Neoadjuvant Chemotherapy.
- Topoisomerase II{alpha} amplification and anthracycline-based chemotherapy: the jury is still out.
- Even low-level HER2 expression may be associated with worse outcome in node-positive breast Cancer.
- Survival among women with triple receptor-negative breast Cancer and brain metastases.
- Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.
- Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast Cancer.
- Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast Cancer.
- Hormone receptor status and pathologic response of HER2-positive breast Cancer treated with neoadjuvant chemotherapy and trastuzumab.
- Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast Cancer.
- Residual risk of breast Cancer recurrence 5 years after adjuvant therapy.
- Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast Cancer cells.
- Gaining ground on breast Cancer.
- Can early response assessment guide neoadjuvant chemotherapy in early-stage breast Cancer?
- Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast Cancer.
- Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast Cancer?
- Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.
- Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast Cancer after initiation of primary chemotherapy.
- Lapatinib induces apoptosis in trastuzumab-resistant breast Cancer cells: effects on insulin-like growth factor I signaling.
- Adenovirus type 5 E1A gene therapy for ovarian clear Cell carcinoma: a potential treatment strategy.
- Novel clinical trial designs for treatment of ductal Carcinoma in situ of the breast with trastuzumab (herceptin).
- The use of HER2 modulation in the adjuvant setting.
- Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast Cancer.
- Adjuvant therapy with trastuzumab for HER-2/neu-positive breast Cancer.
- Long-term cardiac tolerability of trastuzumab in metastatic breast Cancer: the M.D. Anderson Cancer Center experience.
- Tamoxifen-related vasculitis.
- B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast Cancer cells.
- Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast Cancer.
- Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast Cancer.
- Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast Cancer cells.
- The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast Cancer.
- Optimizing outcomes in HER2-positive breast Cancer: the molecular rationale.
- Potential role of mammalian target of rapamycin inhibitors in breast Cancer therapy.
- Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian Cancer xenograft model.
- Epidermal growth factor receptor expression correlates with poor survival in patients who have breast Carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
- Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast Cancer not receiving adjuvant systemic therapy.
- Pathologic changes in breast Cancer following neoadjuvant chemotherapy: implications for the assessment of response.
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
- Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast Carcinoma.
- Expression of Cell cycle inhibitor p27Kip1 and its inactivator Jab1 in melanocytic lesions.
- P27(kip1) down-regulation is associated with trastuzumab resistance in breast Cancer cells.
- Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast Carcinoma.
- The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast Cancer cells.
- Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast Carcinoma.
- Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast Cancer.
- Monoclonal antibodies, small molecules, and vaccines in the treatment of breast Cancer.
- Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast Cancer.
- HER-2-targeted therapy: lessons learned and future directions.
- Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast Cancer.
- Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast Cancer.
- A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast Carcinoma.
- Gene expression profiles obtained from fine-needle aspirations of breast Cancer reliably identify routine prognostic markers and reveal large-scale molecular differenc...
- Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast Carcinoma.
- Multicenter phase II study of oral bexarotene for patients with metastatic breast Cancer.
- Molecular profiles of invasive mucinous and ductal Carcinomas of the breast: a molecular case study.
- Growth factor receptors in breast Cancer: potential for therapeutic intervention.
- Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast Cancer response to chemotherapy.
- Molecular prognostic factors for breast Cancer metastasis and survival.
- Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breas...
- The current status of docetaxel for metastatic breast Cancer.
- Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast Cancer.
- Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast Cancer.
- Breast Carcinoma treatment received by women with disabilities compared with women without disabilities.
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Elected Member
- Fellow (FACP)
Education
-
Georgetown University Hospital -
Cooper University Hospital -
Universidad de Zaragoza Faculty of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center -
NYU Langone Medical Center
Drug Facts
| NPI NUMBER | 1609974245 | |
| NPPES Provider LastName | ESTEVA | |
| NPPES Provider FirstName | FRANCISCO | |
| NPPES Provider ZIPCode | 100164744 | |
| NPPES Provider State | NY | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 198.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 7.58 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1609974245 |
| Last Name Of The Provider | ESTEVA |
| First Name Of The Provider | FRANCISCO |
| View All |
Similar Doctors
|
|
Dr. Anna Belcheva, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ralph G. Zinner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sattva S. Neelapu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelle A. Fanale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria A. Zarzour, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric Jonasch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emer Hanrahan, MD |
|
|
Dr. John V. Heymach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arlene O. Siefker-Radtke, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Theodore F. Tenczynski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Michael Wang |